Terumo (TSE:4543) Jumps 24.5% After Record Full-Year Earnings — What Fueled the Rally and What Comes Next
Terumo Corporation (TSE:4543) saw its shares surge more than 24% after reporting record full-year earnings for the period ended March 31, 2026. The medical device maker posted revenue of ¥1,131.88 billion, up from the prior year, while net income climbed to ¥135.91 billion. Both basic and diluted earnings per share from continuing operations improved year-over-year, signaling that the company’s focus on operational efficiency and cost controls is paying off.
The strong results come amid persistent headwinds from global tariffs and hospital procurement pressures, which have weighed on margins across the med-tech sector. Terumo’s ability to post higher profitability in this environment suggests near-term margin resilience, but the risks are far from gone. If hospital groups continue to push for lower prices and tariff costs escalate, the company may find it increasingly difficult to pass those costs through.
To address these challenges, Terumo recently inaugurated an Offshore Development Center in partnership with Tata Elxsi. The facility is designed to support product development, localization efforts, and cost efficiency. In the context of the solid earnings report, this center could become a key operational lever if pricing pressure intensifies. However, analysts caution that the financial benefits will take time to ripple through the income statement and may not fully offset broader tariff and procurement risks in the near term.
Looking ahead, consensus forecasts project Terumo’s revenue reaching ¥1,335.0 billion and earnings hitting ¥195.4 billion by fiscal 2029, implying a compound annual revenue growth of about 6.8% and a ¥67.5 billion earnings increase from the current base. Based on those projections, some fair-value models suggest a potential upside of roughly 20% from the current share price, with more bullish estimates pushing the fair value as high as 31% above today’s level.
Yet not all analysts are equally optimistic. The most cautious voices point to sustained pricing pressure and procurement dynamics as reasons why today’s strong earnings may not fully address longer-term concerns. They see revenue around ¥1,323.7 billion and earnings of ¥188.7 billion by 2029 — still healthy, but leaving less room for margin expansion.
For shareholders, the bet remains that steady global demand for medical devices will continue, and that Terumo can protect its margins despite headwinds. The latest results reinforce that narrative in the near term, but do not eliminate the key risk that tariffs and hospital pricing power could compress margins if price increases become harder to implement.
This article by Simply Wall St is general in nature. It provides commentary based on historical data and analyst forecasts using an unbiased methodology and is not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of individual objectives or financial situations. The analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 4543.T.